Cross-Sector entity
MarketBeat is most often covered alongside Weiss Ratings, which appears in 10 of these 20 stories. The 13-day window averages about 10.8 stories each week. The busiest single day carried 4. The clearest coverage concentration is markets: 7 of 20 stories, with the rest divided among 9 other categories.
67 verified stories tracked
Last mentioned: 22h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
MarketBeat is most often covered alongside Weiss Ratings, which appears in 10 of these 20 stories. The 13-day window averages about 10.8 stories each week. The busiest single day carried 4. The clearest coverage concentration is markets: 7 of 20 stories, with the rest divided among 9 other categories. Negative sentiment appears in 0% of the tracked stories. Each carries 2 original sources on average. We currently track 20 Cross-Sector stories that mention MarketBeat, published between August 12, 2026 and August 24, 2026.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MarketBeat. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen issues opposing ratings
Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
Wall Street Zen upgrades BKKT and DEI
Wall Street Zen upgraded Bakkt and Douglas Emmett from sell to hold in research notes issued Saturday morning.
Benchmark cuts BKKT target
Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
T1 Energy earnings and BTIG target move
T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
Bakkt reports quarterly results
Bakkt announced EPS of $1.94 and revenue of $170.15 million, missing revenue consensus of $373.27 million.
Truist raises SM Energy target
Increased price target from $37.00 to $43.00 and maintained a Buy rating.
Wall Street Zen cuts STAG and ZVIA to Sell
Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
Cantor Fitzgerald raises DEI target
Cantor Fitzgerald raised its Douglas Emmett target price from $12.00 to $13.00 with a neutral rating.
ZVIA reports Q2 results
Zevia PBC reported EPS of -$0.03, hitting consensus, and revenue of $45.00 million versus a $44.21 million estimate.
SM Energy quarterly results
SM Energy reported $2.19 earnings per share for the quarter.
Douglas Emmett reports earnings
Douglas Emmett reported quarterly EPS of negative $0.02.
Weiss reiterates buy on STAG; Baird sets $138 target
Weiss Ratings reiterated a buy (b-) rating on Stag Industrial, while Robert W. Baird set a $138.00 target price.
STAG reports Q2 earnings miss
Stag Industrial reported EPS of $0.28, missing the consensus estimate of $0.65 by $0.37; revenue was approximately $224 million.
Weiss Ratings upgrades DEI
Weiss Ratings upgraded Douglas Emmett from a sell (d) rating to a sell (d+) rating.
Scotiabank raises DEI target
Scotiabank raised its Douglas Emmett target price from $12.00 to $13.00 with a sector perform rating.
Two updates on SM Energy
Susquehanna lifted its SM target from $31 to $32 (Neutral); Raymond James lowered its target from $55 to $48 (Outperform).
Weiss Ratings upgrades ZVIA within sell range
Weiss Ratings raised shares of Zevia PBC from a sell (e+) rating to a sell (d-) rating.
Barclays raises STAG target but stays Underweight
Barclays boosted its price objective on Stag Industrial from $38.00 to $41.00 and maintained an underweight rating.
UBS initiates SM Energy
Started coverage with a Buy rating and a $36.00 target price.
GrafTech shares trade 2.6% higher
Shares rose to $5.9110 on below-average volume of 206,136 shares, after a prior close of $5.76.
A MarketBeat screener for August 23, 2026 ranks Taiwan Semiconductor, Applied Materials, and Fabrinet among the top-volume manufacturing names, signaling capital flows into semiconductor production capacity. Honeywell Aerospace and Phillips 66 round out the list, tying the signal to aerospace and energy supply chains.
A MarketBeat volume scan for August 23, 2026 flags 19 names across manufacturing, penny, and mid-cap categories, including semiconductor heavyweights, six crypto miners, two airlines, and a leveraged TSLA ETF. The mix points to broad speculative and cyclical positioning rather than a single sector theme.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Source: themarketsdaily.com · dailypolitical.com
A dollar-volume screen put Palo Alto Networks, CrowdStrike, and Fortinet atop the cybersecurity group on August 21 — a liquidity snapshot showing investor conviction concentrating in scaled, AI-native security platforms. The same day, PANW and CRWD both traded higher, with CRWD's gen-AI workload security noted as a key differentiator.
Bitdeer, Core Scientific, and Figure led blockchain-stock dollar volume on August 21, with CORZ up 4.1% while BTDR slipped 1.2% as bitcoin held near $118,450. The screen highlights how mining equities trade as liquid, leveraged proxies for BTC.
Source: themarketsdaily.com · dailypolitical.com
MarketBeat's August 19 high-volume value screen names Moderna, QQQ, Intel, Nebius, and SpaceX, while a large-cap screen adds SanDisk and Micron. The list highlights where dollar volume concentrated, but classifications include an ETF and a private company, so investors should validate the data before acting.
Moderna appears on both MarketBeat's value and large-cap high-volume screens on August 19, underscoring unusual liquidity and renewed biotech interest despite a post-COVID valuation reset. The mRNA pipeline spans respiratory, latent, and public health vaccines, setting up multiple clinical catalysts.
Source: watchlistnews.com · tickerreport.com
Applied Digital shares slid 8.6% to $28.51 despite a Moderate Buy consensus and an average target of $68.15. The decline highlights a growing divide between sell-side optimism and trader concerns about negative earnings and elevated leverage.
Applied Digital's 8.6% drop to $28.51, paired with a 5.1% fall in quantum peer Rigetti, signals cooling sentiment toward AI-adjacent infrastructure stocks after APLD's July earnings miss. High beta and negative EPS are forcing AI investors to reassess execution risk.
Source: themarketsdaily.com · dailypolitical.com
Wall Street Zen's sell-to-hold upgrade for Bakkt comes as the stock trades at $7.66 with a $341.53 million market cap. The move follows a 54% revenue miss and a director's $783,000 insider buy, leaving analysts divided on whether this is a bottom or a value trap.
Crypto platform Bakkt's sell-to-hold upgrade masks a brutal year: shares at $7.66 are down 85% from $49.79. A director's insider buy and an extreme beta of 5.91 frame the risk-reward for Web3 investors watching custody and exchange infrastructure.
Source: tickerreport.com · themarketsdaily.com
A head-to-head comparison of two small-cap tech names reveals a sharp risk divergence: Key Tronic's 1.19 beta and 40.7% institutional backing contrast with Schmitt Industries' rare negative -0.21 beta and 17.1% insider ownership. Investors must decide between a contract manufacturer with above-market volatility and a niche instrumentation play with inverse correlation to the S&P 500.
Source: dailypolitical.com · tickerreport.com
For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Source: dailypolitical.com · tickerreport.com
MarketBeat's screener surfaced five blockchain equities with the highest dollar volume on July 25, 2026: Core Scientific, Bitdeer, Globant, Figure Technology Solutions, and Digi Power X. For crypto-native investors, these public names offer indirect exposure to mining, infrastructure, and blockchain services without directly holding BTC. The list underscores where liquidity is rotating among blockchain-linked stocks amid continued volatility.
Source: tickerreport.com · dailypolitical.com
Wall Street Zen cut Stag Industrial to sell, putting a fresh bearish tilt on a REIT whose shares opened at $36.68 versus a $50.50 consensus target. The same firm also downgraded Zevia PBC as its major shareholder trimmed a 15.87% stake.
Source: tickerreport.com · dailypolitical.com
Weave Communications, a healthcare SaaS and payments vendor, beats Surgical Science Sweden on six of nine factors. Its $8.33 consensus target and 86.8% institutional ownership highlight investor confidence in its SMB healthcare platform.
A head-to-head survey gives Weave Communications a stronger rating and 27.58% upside over Surgical Science Sweden, but the two health companies serve very different markets: patient engagement software versus surgical simulation.
Source: tickerreport.com · dailypolitical.com
GrafTech's 2.6% daily rise obscures deeper weakness: analyst downgrades, an EPS miss of $0.80, and a market cap of just $154M. For supply chain professionals, the move is a reminder to watch graphite electrode pricing and supplier financial health.
Source: tickerreport.com · dailypolitical.com
Shares of Entera Bio slipped 0.6% to $1.54 on 78% below-average volume, but analysts remain deeply split: HC Wainwright reiterates buy while Weiss Ratings maintains a sell. The $9.00 consensus target implies roughly 484% upside for the $75.91M microcap biotech.
Source: dailypolitical.com · tickerreport.com
